Answers are grounded in this paper and cite their sources.
In vitro study uncovers presentation of intron retention neoepitopes on MHC I in cancer cells, highlighting new targets for personalized cancer vaccines.
Neoepitopes derived from intron retention events are processed and presented on MHC I in cancer cell lines. We present an in silico approach to identifying neoepitopes derived from intron retention events in tumor transcriptomes. Using mass spectrometry immunopeptidome analysis, we show that retained intron neoepitopes are processed and presented on MHC I on the surface of cancer cell lines. RNA-derived neoepitopes should be considered for prospective personalized cancer vaccine development.
No takes yet. Share an insight, caveat, or question.
Smart et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: